[go: up one dir, main page]

WO2004066957A3 - Preparation d'anticorps anti-integrine $g(a)v$g(b)3 et utilisations associees - Google Patents

Preparation d'anticorps anti-integrine $g(a)v$g(b)3 et utilisations associees Download PDF

Info

Publication number
WO2004066957A3
WO2004066957A3 PCT/US2004/002701 US2004002701W WO2004066957A3 WO 2004066957 A3 WO2004066957 A3 WO 2004066957A3 US 2004002701 W US2004002701 W US 2004002701W WO 2004066957 A3 WO2004066957 A3 WO 2004066957A3
Authority
WO
WIPO (PCT)
Prior art keywords
integrin ανβ3
formulations
antibodies
present
disorder associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/002701
Other languages
English (en)
Other versions
WO2004066957A2 (fr
Inventor
Christian B Allan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Priority to JP2006503199A priority Critical patent/JP2006516636A/ja
Priority to AU2004207003A priority patent/AU2004207003A1/en
Priority to CA002512174A priority patent/CA2512174A1/fr
Priority to EP04707034A priority patent/EP1589996A4/fr
Publication of WO2004066957A2 publication Critical patent/WO2004066957A2/fr
Publication of WO2004066957A3 publication Critical patent/WO2004066957A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des préparations liquides d'anticorps ou de fragments d'anticorps qui se lient de manière immunospécifique à l'intégrine α?β3 et qui présentent une certaine stabilité, des niveaux d'agrégation faibles voire indécelables, et très peu voire pas de perte des activités biologiques des anticorps ou des fragments d'anticorps, même durant de longues périodes de stockage. Notamment, cette invention a pour objet des préparations liquides d'anticorps ou de fragments associés qui se lient de manière immunospécifique à l'intégrine α?β3 et qui sont pratiquement exemptes d'agent de surface, de sels minéraux et/ou d'autres excipients communs. De plus, ladite invention a trait à des méthodes de prévention, de traitement ou d'amélioration d'un trouble inflammatoire, d'un trouble auto-immun, d'un trouble lié à l'expression aberrante et/ou à l'activité de l'intégrine α?β3, d'un trouble associé à un métabolisme osseux anormal, d'un trouble lié à une angiogenèse aberrante ou à un cancer, au moyen desdites préparations liquides de cette invention.
PCT/US2004/002701 2003-01-30 2004-01-30 Preparation d'anticorps anti-integrine $g(a)v$g(b)3 et utilisations associees Ceased WO2004066957A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2006503199A JP2006516636A (ja) 2003-01-30 2004-01-30 抗インテグリンαｖβ３抗体製剤及びその用途
AU2004207003A AU2004207003A1 (en) 2003-01-30 2004-01-30 Anti-integrin alphanubeta3 antibody formulations and uses thereof
CA002512174A CA2512174A1 (fr) 2003-01-30 2004-01-30 Formulations d'anticorps anti-integrine .alpha..nu..beta.3 et utilisations connexes
EP04707034A EP1589996A4 (fr) 2003-01-30 2004-01-30 Preparation d'anticorps anti-integrine alpha beta 3 et utilisations associees

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44381003P 2003-01-30 2003-01-30
US44377703P 2003-01-30 2003-01-30
US60/443,810 2003-01-30
US60/443,777 2003-01-30

Publications (2)

Publication Number Publication Date
WO2004066957A2 WO2004066957A2 (fr) 2004-08-12
WO2004066957A3 true WO2004066957A3 (fr) 2005-04-07

Family

ID=32829839

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/002701 Ceased WO2004066957A2 (fr) 2003-01-30 2004-01-30 Preparation d'anticorps anti-integrine $g(a)v$g(b)3 et utilisations associees

Country Status (5)

Country Link
EP (1) EP1589996A4 (fr)
JP (1) JP2006516636A (fr)
AU (1) AU2004207003A1 (fr)
CA (1) CA2512174A1 (fr)
WO (1) WO2004066957A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US9017671B2 (en) 2004-10-20 2015-04-28 Genentech, Inc. Method of treating cancer with a pharmaceutical formulation comprising a HER2 antibody

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973134B2 (en) 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
US20060046961A1 (en) * 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
US7935790B2 (en) 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
US7807789B2 (en) 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
NZ564843A (en) * 2005-08-03 2012-05-25 Immunogen Inc Immunoconjugate formulations comprising an immunoconjugate and an excipient in a buffered aqueous solution
EP1934867A2 (fr) 2005-08-31 2008-06-25 Cell Signaling Technology, Inc. Reactifs de detection de phosphorylation proteinique dans des voies de signalisation de leucemie
EP2001490A1 (fr) 2006-03-15 2008-12-17 Alexion Pharmaceuticals, Inc. Traitement de patients souffrant d'hemoglobinurie paroxystique nocturne par un inhibiteur de complement
US7939636B2 (en) 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
EP2061810B1 (fr) 2006-09-05 2014-11-12 Alexion Pharmaceuticals, Inc. Procédés et compositions de traitement de neuropathies induites par des antibiotiques
EP2094247B1 (fr) 2006-10-20 2022-06-29 Amgen Inc. Formulations stables de polypeptide
US20090081659A1 (en) 2007-03-07 2009-03-26 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1975184A3 (fr) 2007-03-26 2008-11-26 Cell Signaling Technology, Inc. Sites de phosphorylation à sérine ou thréonine
RU2476442C2 (ru) 2007-03-29 2013-02-27 Эббот Лэборетриз Кристаллические антитела против il-12 человека
EP1983002A3 (fr) 2007-04-19 2009-03-11 Peter Hornbeck Sites de phosphorylation à tyrosine et anticorps spécifiques
EP1983003A3 (fr) 2007-04-19 2009-03-11 Peter Hornbeck Sites de phosphorylation à tyrosine et anticorps spécifiques
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
ES2367409T3 (es) * 2007-10-09 2011-11-03 Hercules Incorporated Composiciones adhesivas que contienen reticulante.
US20090203043A1 (en) 2007-11-21 2009-08-13 Peter Hornbeck Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
CA2791905A1 (fr) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarqueurs pour theranostique
WO2011121560A2 (fr) * 2010-03-31 2011-10-06 Universite De Geneve Préparations d'anticorps stabilisés et utilisations correspondantes
BR112012025593A2 (pt) 2010-04-06 2019-06-25 Caris Life Sciences Luxembourg Holdings biomarcadores em circulação para doença
NZ629204A (en) * 2012-02-16 2016-09-30 Santarus Inc Anti-vla1 (cd49a) antibody pharmaceutical compositions
CA2964786C (fr) 2014-10-23 2023-10-17 Amgen Inc. Reduction de la viscosite de formulations pharmaceutiques avec des acides amines n-acetyle
EP3901162A1 (fr) 2016-06-02 2021-10-27 AbbVie Inc. Agoniste du récepteur des glucocorticoïdes et immunoconjugués de celui-ci
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
JP6813712B2 (ja) 2017-12-01 2021-01-13 アッヴィ・インコーポレイテッド グルココルチコイド受容体作動薬及びそのイムノコンジュゲート
WO2020060183A1 (fr) * 2018-09-18 2020-03-26 삼성바이오에피스 주식회사 Formation de liquide pour stabiliser un anticorps de trastuzumab
US20220091135A1 (en) * 2019-01-04 2022-03-24 Kyoto University Test method for ulcerative colitis and primary sclerosing cholangitis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US20010016645A1 (en) * 1997-01-30 2001-08-23 Ixsys, Incorporated Anti-alphavbeta3 recombinant human antibodies, nucleic acids encoding same and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1314437E (pt) * 2000-08-11 2014-08-29 Chugai Pharmaceutical Co Ltd Preparações estabilizadas contendo anticorpo

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US20010016645A1 (en) * 1997-01-30 2001-08-23 Ixsys, Incorporated Anti-alphavbeta3 recombinant human antibodies, nucleic acids encoding same and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1589996A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017671B2 (en) 2004-10-20 2015-04-28 Genentech, Inc. Method of treating cancer with a pharmaceutical formulation comprising a HER2 antibody
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same

Also Published As

Publication number Publication date
WO2004066957A2 (fr) 2004-08-12
CA2512174A1 (fr) 2004-08-12
AU2004207003A1 (en) 2004-08-12
JP2006516636A (ja) 2006-07-06
EP1589996A4 (fr) 2009-01-21
EP1589996A2 (fr) 2005-11-02

Similar Documents

Publication Publication Date Title
WO2004066957A3 (fr) Preparation d'anticorps anti-integrine $g(a)v$g(b)3 et utilisations associees
WO2006133955A8 (fr) Compositions contenant adamts13, presentant une activite thrombolytique
WO2002028999A3 (fr) Profils d'expression genique dans les cellules granulocytaires
WO2006138418A3 (fr) Amelioration de la performance cognitive avec des activateurs de sirtuine
WO2005117967A3 (fr) Preparations d'anticorps anti-il-9 et leurs applications
TW200806317A (en) Methods for reducing protein aggregation
WO2005065418A3 (fr) Compositions et procedes d'utilisation de peptides de ciblage pour le diagnostic et la therapie
WO2007044323A3 (fr) Proteines de fusion pour administration a travers la barriere hemato-encephalique
WO2007104792A3 (fr) Adénovirus recombinés basés sur les sérotypes 26 et 48 et utilisation de ceux-ci
WO2008022349A3 (fr) Agents pour barrière hémato-encéphalique
TNSN07304A1 (en) Combination of xolair with immunosuppressive agent
WO2004089396A3 (fr) Composes antifongiques et leurs procedes de mise en oeuvre
WO2006058318A3 (fr) Dispositifs donneurs de monoxyde d'azote topiques et leurs methodes d'utilisation a des fins therapeutiques
MY139142A (en) Short corridor progressive addition lenses with reduced unwanted astigmatism
WO2008157483A3 (fr) Polypeptides et procédés d'utilisation
WO2009018226A3 (fr) Combinaisons pharmaceutiques
WO2006105359A3 (fr) Methodes pour stimuler la pousse des cheveux par administration de proteines bmp
WO2005009366A3 (fr) Restauration d'une fonction vasculaire
WO2017160699A3 (fr) Méthode de traitement de la réaction du greffon contre l'hôte (gvd)
WO2009069288A1 (fr) Produit de soins capillaires
WO2004078927A3 (fr) Cellules progenitrices et procedes d'utilisation
WO2015038925A3 (fr) Nouvelles compositions d'administration et méthodes d'utilisation de ces dernières
BRPI0406744A (pt) Artigo absorvente de higiene feminina
WO2006116185A3 (fr) Procedes destines au traitement de myelomes multiples
WO2005094391A3 (fr) COMPOSITIONS ET METHODES DE TRAITEMENT ET DE PREVENTION D'UNE MALADIE ASSOCIEE A L'INTEGRINE αVβ5

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2512174

Country of ref document: CA

Ref document number: 2006503199

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004207003

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004707034

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004207003

Country of ref document: AU

Date of ref document: 20040130

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004207003

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004707034

Country of ref document: EP